JP2008520739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520739A5 JP2008520739A5 JP2007543444A JP2007543444A JP2008520739A5 JP 2008520739 A5 JP2008520739 A5 JP 2008520739A5 JP 2007543444 A JP2007543444 A JP 2007543444A JP 2007543444 A JP2007543444 A JP 2007543444A JP 2008520739 A5 JP2008520739 A5 JP 2008520739A5
- Authority
- JP
- Japan
- Prior art keywords
- dpan
- oil
- dihydroxy
- dtan
- lcpufa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 80
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 66
- 239000003921 oil Substances 0.000 claims 49
- 235000019198 oils Nutrition 0.000 claims 49
- 150000002026 docosanoids Chemical class 0.000 claims 46
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims 40
- 238000000034 method Methods 0.000 claims 38
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 33
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 31
- MZQXAWAWDWCIKG-SPSBLGDNSA-N Avenoleic acid Chemical class CCC[C@@H](O)C\C=C/C\C=C/CCCCCCCC(O)=O MZQXAWAWDWCIKG-SPSBLGDNSA-N 0.000 claims 21
- 102000004190 Enzymes Human genes 0.000 claims 15
- 108090000790 Enzymes Proteins 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 13
- KFINXCASWPGHEW-UHFFFAOYSA-N (9S*,10R*,11R*,12Z,15Z)-9,10,11-trihydroxyoctadeca-12,15-dienoic acid Natural products CCC=CCC=CC(O)C(O)C(O)CCCCCCCC(O)=O KFINXCASWPGHEW-UHFFFAOYSA-N 0.000 claims 12
- 244000005700 microbiome Species 0.000 claims 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 8
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 7
- 238000000746 purification Methods 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000000758 substrate Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 4
- 239000004593 Epoxy Substances 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 108090000128 Lipoxygenases Proteins 0.000 claims 4
- 102000003820 Lipoxygenases Human genes 0.000 claims 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 4
- 102000001554 Hemoglobins Human genes 0.000 claims 3
- 108010054147 Hemoglobins Proteins 0.000 claims 3
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 claims 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 238000004061 bleaching Methods 0.000 claims 3
- 230000001877 deodorizing effect Effects 0.000 claims 3
- 238000000605 extraction Methods 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 102100024902 Cytochrome P450 4F2 Human genes 0.000 claims 2
- 101000909122 Homo sapiens Cytochrome P450 4F2 Proteins 0.000 claims 2
- 102100033075 Prostacyclin synthase Human genes 0.000 claims 2
- 239000010775 animal oil Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000008158 vegetable oil Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 claims 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 claims 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 claims 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 claims 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 claims 1
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 claims 1
- 102100027567 Cytochrome P450 4A11 Human genes 0.000 claims 1
- 102100027419 Cytochrome P450 4B1 Human genes 0.000 claims 1
- 102100024916 Cytochrome P450 4F11 Human genes 0.000 claims 1
- 102100024918 Cytochrome P450 4F12 Human genes 0.000 claims 1
- 102100024901 Cytochrome P450 4F3 Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000725111 Homo sapiens Cytochrome P450 4A11 Proteins 0.000 claims 1
- 101000909111 Homo sapiens Cytochrome P450 4F11 Proteins 0.000 claims 1
- 101000909108 Homo sapiens Cytochrome P450 4F12 Proteins 0.000 claims 1
- 101000909121 Homo sapiens Cytochrome P450 4F3 Proteins 0.000 claims 1
- 101000653005 Homo sapiens Thromboxane-A synthase Proteins 0.000 claims 1
- 101710179550 Prostacyclin synthase Proteins 0.000 claims 1
- 241001467333 Thraustochytriaceae Species 0.000 claims 1
- 102100030973 Thromboxane-A synthase Human genes 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 238000006701 autoxidation reaction Methods 0.000 claims 1
- 230000031018 biological processes and functions Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 108010018719 cytochrome P-450 CYP4B1 Proteins 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 108010064377 prostacyclin synthetase Proteins 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62984204P | 2004-11-19 | 2004-11-19 | |
| US72903805P | 2005-10-21 | 2005-10-21 | |
| PCT/US2005/042462 WO2006055965A2 (en) | 2004-11-19 | 2005-11-21 | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520739A JP2008520739A (ja) | 2008-06-19 |
| JP2008520739A5 true JP2008520739A5 (https=) | 2009-01-15 |
Family
ID=36407879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543444A Pending JP2008520739A (ja) | 2004-11-19 | 2005-11-21 | 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7884131B2 (https=) |
| EP (1) | EP1824809A4 (https=) |
| JP (1) | JP2008520739A (https=) |
| KR (1) | KR20070090928A (https=) |
| CN (1) | CN101102988B (https=) |
| AU (1) | AU2005306320B2 (https=) |
| BR (1) | BRPI0516803A (https=) |
| CA (1) | CA2588166A1 (https=) |
| EA (1) | EA010802B1 (https=) |
| IL (1) | IL183246A0 (https=) |
| MX (1) | MX2007006049A (https=) |
| NZ (1) | NZ555394A (https=) |
| WO (1) | WO2006055965A2 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318394A1 (en) * | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
| US7893106B2 (en) * | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| BRPI0613358A8 (pt) * | 2005-07-08 | 2017-12-26 | Dsm Ip Assets Bv | ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência |
| WO2007041440A2 (en) * | 2005-10-03 | 2007-04-12 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers |
| US20090320148A1 (en) * | 2006-01-31 | 2009-12-24 | Martek Biosciences Corporation | Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same |
| GB0604647D0 (en) | 2006-03-08 | 2006-04-19 | Shchepinov Mikhail | Stabilized food supplements and their derivatives |
| CA2650607A1 (en) * | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
| MX2009000657A (es) * | 2006-07-19 | 2009-05-28 | Resolvyx Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de mucositis. |
| WO2008057283A2 (en) * | 2006-10-26 | 2008-05-15 | Resolvyx Pharmaceuticals, Inc. | Use of resolvins for inhibition of bone loss |
| WO2008070129A2 (en) * | 2006-12-05 | 2008-06-12 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
| WO2008103753A2 (en) * | 2007-02-20 | 2008-08-28 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
| RU2009139002A (ru) * | 2007-03-23 | 2011-04-27 | Новартис АГ (CH) | Применение замаскированной или с нанесенным на нее покрытием соли меди для лечения дегенерации желтого пятна |
| US20100159540A1 (en) * | 2007-03-26 | 2010-06-24 | Ana Rodriguez | Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof |
| WO2009017802A1 (en) | 2007-08-01 | 2009-02-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nitro-fattyacid modulation of type ii diabetes |
| CA2699483A1 (en) * | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
| JP5421272B2 (ja) * | 2007-10-12 | 2014-02-19 | リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド | 眼病治療のための組成物及び方法 |
| WO2009086281A1 (en) * | 2007-12-21 | 2009-07-09 | Martek Biosciences Corporation | Method for preparation of oxylipins |
| JP2011519373A (ja) | 2008-05-01 | 2011-07-07 | コンプレクザ インコーポレイテッド | ビニル置換脂肪酸 |
| EP2299997A4 (en) | 2008-06-19 | 2012-01-11 | Univ Utah Res Found | USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| EP2344441B1 (en) * | 2008-09-16 | 2016-02-17 | The Brigham And Women's Hospital Inc. | 7,14-dihydroxy-docosahexaenoic acid compounds |
| JP6113954B2 (ja) * | 2008-10-31 | 2017-04-12 | リピッド ファーマシューティカルズ イーエイチエフ． | 医薬として使用するための脂肪酸 |
| WO2010095706A1 (ja) * | 2009-02-20 | 2010-08-26 | 国立大学法人東京大学 | 新規抗炎症性化合物 |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| DK2429317T4 (da) * | 2009-04-17 | 2019-05-13 | Natac Pharma S L | Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| EP3045167A1 (en) | 2009-07-31 | 2016-07-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Keto fatty acids as anti-inflammatory agents |
| WO2011028689A1 (en) | 2009-09-01 | 2011-03-10 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| USRE46608E1 (en) | 2009-09-01 | 2017-11-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
| EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
| US10052299B2 (en) | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| JP5909183B2 (ja) * | 2010-08-19 | 2016-04-26 | 国立大学法人 東京大学 | オメガ３系脂肪酸由来の新規抗炎症性代謝物 |
| WO2012026106A1 (ja) * | 2010-08-25 | 2012-03-01 | 国立大学法人 東京大学 | 光学活性な新規抗炎症性化合物及びその製造方法 |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2012148930A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Oxidative retinal diseases |
| KR102112087B1 (ko) | 2011-04-26 | 2020-05-18 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
| JP6145087B2 (ja) | 2011-04-26 | 2017-06-07 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ酸化関与障害 |
| JP6106157B2 (ja) | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 神経変性障害および筋疾患に関与するｐｕｆａ |
| US9416118B2 (en) * | 2011-06-10 | 2016-08-16 | The Brigham And Women's Hospital, Inc. | Docosahexaenoyl ethanolamides |
| WO2013028501A1 (en) | 2011-08-19 | 2013-02-28 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
| US10322118B2 (en) * | 2012-04-10 | 2019-06-18 | Trustees Of Dartmouth College | Compounds and methods for inhibiting Cif virulence factor |
| DK2858496T3 (da) * | 2012-05-10 | 2023-07-24 | Solutex Na Llc | Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere |
| EP2861227A4 (en) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
| HK1211867A1 (en) | 2012-08-24 | 2016-06-03 | Sun Pharma Global Fze | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
| WO2014110261A1 (en) * | 2013-01-11 | 2014-07-17 | Massachusetts Eye And Ear Infirmary | Cyp450 lipid metabolites reduce inflammation and angiogenesis |
| WO2014130894A1 (en) * | 2013-02-21 | 2014-08-28 | University Of Southern California | Compositions for the treatment of inflammatory diseases |
| CA2905671A1 (en) * | 2013-03-13 | 2014-09-18 | Matinas Biopharma Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| EP3892608B1 (en) | 2013-05-30 | 2025-07-23 | The Brigham and Women's Hospital, Inc. | Novel n-3 immunoresolvents: structures and actions |
| AU2016219517B2 (en) * | 2015-02-09 | 2020-02-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| HK1256301A1 (zh) * | 2015-07-20 | 2019-09-20 | The Brigham And Women's Hospital, Inc. | 提高阿托伐他汀和清除感染的新的 13 系列消退素的说明 |
| US10653703B2 (en) | 2015-09-03 | 2020-05-19 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
| WO2017059451A1 (en) | 2015-10-02 | 2017-04-06 | Complexa, Inc. | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
| WO2017083167A1 (en) | 2015-11-10 | 2017-05-18 | Ocular Technologies Sarl | Topical formulations and uses thereof |
| EP3950649A1 (en) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| WO2019104315A1 (en) * | 2017-11-27 | 2019-05-31 | Brown University | Compositions and methods using lipids for treating neurological disease |
| WO2019104311A1 (en) * | 2017-11-27 | 2019-05-31 | Brown University | Compositions and methods for suppressing neurological disease |
| EP3792351A4 (en) | 2018-04-16 | 2022-01-19 | Korea Research Institute of Bioscience and Biotechnology | Method for producing multi-hydroxy derivatives of polyunsaturated fatty acids |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| CA3110680A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| KR102673270B1 (ko) * | 2018-10-15 | 2024-06-07 | (주)아모레퍼시픽 | 피부장벽 강화용 조성물 |
| KR102704402B1 (ko) | 2018-10-24 | 2024-09-06 | (주)아모레퍼시픽 | 피부장벽 강화용 조성물 |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| IL295783B2 (en) | 2020-02-21 | 2026-03-01 | Retrotope Inc | Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| KR20220159751A (ko) | 2021-05-26 | 2022-12-05 | (주)아모레퍼시픽 | 미백용 조성물 및 이를 이용한 피부 미백방법 |
| WO2024229108A1 (en) * | 2023-05-01 | 2024-11-07 | The Regents Of The University Of California | In-situ production of anti-inflammatory lipids using milk fat globules |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63238075A (ja) * | 1987-03-24 | 1988-10-04 | Mitsumaru Kagaku Kk | 高度不飽和脂肪酸からのラクトン類の製造法 |
| US4866046A (en) * | 1988-05-31 | 1989-09-12 | Top Laboratories, Inc. | Low-dosage sublingual aspirin |
| US5102670A (en) | 1990-09-14 | 1992-04-07 | Abraham Nader G | Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels |
| JPH05286956A (ja) * | 1992-04-06 | 1993-11-02 | Nippon Suisan Kaisha Ltd | ドコサペンタエン酸モノエポキシ体、及びその製造法 |
| US6887901B1 (en) | 1993-06-15 | 2005-05-03 | Brigham & Women's Hospital, Inc. | Lipoxin compounds and their use in treating cell proliferative disorders |
| GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| CZ281096B6 (cs) * | 1994-06-30 | 1996-06-12 | Jindřich Mudr. Drsc. Mourek | Tuková složka mléčné výživy a dětská výživa |
| US5955496A (en) | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
| CN1109543C (zh) | 1996-10-11 | 2003-05-28 | 斯卡里斯塔有限公司 | 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂 |
| US6174695B1 (en) | 1997-08-12 | 2001-01-16 | The Regents Of The University Of California | Epoxide hydrolase inhibitor methods |
| DE19757414A1 (de) | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
| JPH11209259A (ja) * | 1998-01-20 | 1999-08-03 | Noevir Co Ltd | 皮膚化粧料 |
| CA2362515C (en) | 1999-03-04 | 2008-07-15 | Suntory Limited | Utilization of material containing docosapentaenoic acid |
| JP4474082B2 (ja) | 1999-07-07 | 2010-06-02 | キリン協和フーズ株式会社 | 水酸化脂肪酸およびδ−ラクトン類の製造方法 |
| HK1045985B (en) | 1999-11-09 | 2004-04-23 | Alcon, Inc. | 15-hydroxyeicosatetraenoic acid-related compounds and methods of use |
| EP1762557B1 (en) * | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| DE10046541A1 (de) | 2000-09-19 | 2002-03-28 | Knoll Ag | Mechanisch stabile darreichungsformen, enthaltend Ubichinone |
| WO2002029018A2 (en) | 2000-10-06 | 2002-04-11 | Michigan State University | Divinyl ether synthase gene and protein, and uses thereof |
| AU2002309856B2 (en) * | 2001-05-14 | 2008-10-23 | Dsm Ip Assets B.V. | Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms |
| WO2003053423A2 (en) * | 2001-12-18 | 2003-07-03 | The Brigham And Women's Hospital | Inhibition or prevention of infection by bacteria with epa, dha or analogs |
| US7527935B2 (en) | 2002-03-19 | 2009-05-05 | Mitsubishi Tanabe Pharma Corporation | G-protein coupled receptor having eicosanoid as ligand and gene thereof |
| US7582785B2 (en) | 2002-04-01 | 2009-09-01 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
| AU2003260687A1 (en) | 2002-04-01 | 2003-10-20 | University Of Southern California | Trihydroxy polyunsaturated eicosanoids |
| FR2843124B1 (fr) | 2002-08-02 | 2004-10-15 | Goemar Lab Sa | Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation |
| DE60330154D1 (de) * | 2002-08-12 | 2009-12-31 | Brigham & Womens Hospital | Resolvine: biotemplate zur durchführung therapeutischer anwendungen |
| US20040166130A1 (en) | 2002-12-23 | 2004-08-26 | L'oreal | Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
-
2005
- 2005-11-21 BR BRPI0516803-1A patent/BRPI0516803A/pt not_active IP Right Cessation
- 2005-11-21 US US11/284,790 patent/US7884131B2/en not_active Expired - Fee Related
- 2005-11-21 EP EP05846821A patent/EP1824809A4/en not_active Withdrawn
- 2005-11-21 AU AU2005306320A patent/AU2005306320B2/en not_active Ceased
- 2005-11-21 CN CN2005800468877A patent/CN101102988B/zh not_active Expired - Fee Related
- 2005-11-21 KR KR1020077013738A patent/KR20070090928A/ko not_active Ceased
- 2005-11-21 JP JP2007543444A patent/JP2008520739A/ja active Pending
- 2005-11-21 MX MX2007006049A patent/MX2007006049A/es active IP Right Grant
- 2005-11-21 NZ NZ555394A patent/NZ555394A/en not_active IP Right Cessation
- 2005-11-21 WO PCT/US2005/042462 patent/WO2006055965A2/en not_active Ceased
- 2005-11-21 EA EA200701100A patent/EA010802B1/ru not_active IP Right Cessation
- 2005-11-21 CA CA002588166A patent/CA2588166A1/en not_active Abandoned
-
2007
- 2007-05-15 IL IL183246A patent/IL183246A0/en unknown
-
2010
- 2010-12-29 US US12/981,261 patent/US20110178047A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520739A5 (https=) | ||
| JP2010519311A5 (https=) | ||
| US7893106B2 (en) | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same | |
| US7884131B2 (en) | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same | |
| US20110190389A1 (en) | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same | |
| Singh et al. | Ecological dynamics and biotechnological implications of thraustochytrids from marine habitats | |
| US20090318394A1 (en) | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same | |
| JPH0591887A (ja) | ジホモ−γ−リノレン酸及びこれを含有する脂質の製造方法 | |
| Zhang et al. | Advances in enzyme biocatalysis for the preparation of functional lipids | |
| JP2005102680A (ja) | ドコサヘキサエン酸生産能を有する微生物及びその利用 | |
| US20090320148A1 (en) | Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same | |
| Roby | Synthesis and characterization of phenolic lipids | |
| El-Baz et al. | Single cell oil (SCO)–based bioactive compounds: I—enzymatic synthesis of fatty acid amides using SCOs as acyl group donors and their biological activities | |
| US20170327851A1 (en) | Microalgae Aurantiochytrium sp. LA3 (KCTC12685BP) and Method for Preparing Bio-Oil Using the Same | |
| Cho et al. | Growth medium sterilization using decomposition of peracetic acid for more cost-efficient production of omega-3 fatty acids by Aurantiochytrium | |
| EP1608731A2 (en) | A method of enhancing levels of polyunsaturated fatty acids in thraustochytrid protists | |
| JP2004285182A (ja) | グリセリドおよびその製造方法 | |
| JP2010094111A (ja) | 高度不飽和脂肪酸の製造方法 | |
| AU2011253846A1 (en) | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same | |
| JPH0582197B2 (https=) | ||
| JP2006061021A (ja) | １種類の高度不飽和脂肪酸残基３個から成るトリグリセライドの製造方法、およびその利用 | |
| JP2018082676A (ja) | 構造油脂の製造方法 | |
| KR20260042216A (ko) | 높은 epa 함량을 갖는 미생물 오일 및 이의 제조 방법 | |
| US20110027841A1 (en) | Method for preparation of oxylipins | |
| JP2010042037A (ja) | １種類の高度不飽和脂肪酸残基３個から成るトリグリセライドの製造方法、およびその利用 |